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Abstract
Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor
pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations
in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic
response to different oncogenic drivers or a particular oncogenic event results in its own metabolic
reprogramming. Akt and Myc are arguably the most prevalent driving oncogenes in prostate cancer. Mass
spectrometry–based metabolite proﬁling was performed on immortalized human prostate epithelial cells
transformed by AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a prostate-
speciﬁc promoter, and human prostate specimens characterized for the expression and activation of these
oncoproteins. Integrative analysis of these metabolomic datasets revealed that AKT1 activation was
associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated
with dysregulated lipid metabolism. Selected metabolites that differentially accumulated in the MYC-high
versus AKT1-high tumors, or in normal versus tumor prostate tissue by untargeted metabolomics, were
validated using absolute quantitation assays. Importantly, the AKT1/MYC status was independent of Gleason
grade and pathologic staging. Our ﬁndings show how prostate tumors undergo a metabolic reprogramming
that reﬂects their molecular phenotypes, with implications for the development of metabolic diagnostics and
targeted therapeutics. Cancer Res; 74(24); 7198–204. 2014 AACR.
Introduction
Metabolomics allows unbiased identiﬁcation of subtle
changes in metabolite proﬁles as affected by signaling path-
ways or genetic factors (1–3). Metabolic alterations may rep-
resent the integration of genetic regulation, enzyme activity,
and metabolic reactions. In addition, because the known
metabolome is considerably smaller than the number of genes,
transcripts, or proteins, metabolomics may more clearly char-
acterize altered cellular networks (4). Clinically, metabolic
imaging technologies such as PET, can be used to monitor
disease progression and drug response (5).
Genomic loss of the PTEN locus, leading to constitutive
activation of the PI3K/AKT pathway, and 8q ampliﬁcation,
including the MYC gene, occurs in 30% to 70% and approxi-
mately 30% of prostate tumors, respectively (6), representing
the most frequent genetic alterations in prostate cancer. Both
activated AKT and in particular MYC overexpression faithfully
reproduce the stages of human prostate carcinogenesis in
genetically engineered mice (7, 8).
While MYC promotes glutaminolysis (9, 10), AKT activation
is associated with enhanced aerobic glycolysis (the "Warburg
effect"; ref. 11) and/or increased expression of glycolytic
enzymes in different cell types, including prostate (12). How-
ever, the impact of these oncogenes (or the genomic alterations
causing their activation) on the metabolome of human pros-
tate tumors has not yet been elucidated.
Materials and Methods
Generation of AKT1- and MYC-overexpressing RWPE-1
Immortalized human prostate epithelial RWPE-1 cells were
obtained from Novartis and conﬁrmed to be nontumorigenic
(growth in soft agar) before performing the experiments.
RWPE-1 was authenticated by DDC Medical. Cells were
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infected with pBABE vector alone (RWPE–EV), myristoylated
AKT1 (RWPE-AKT1) or MYC (RWPE–MYC). Brieﬂy, cells were
transduced through infection in the presence of polybrene
(8 mg/mL), and retroviral supernatants were replaced with
fresh media after 4 hours of incubation. Twenty-four hours
later, puromycin selection (1 mg/mL) was started. Cells were
grown in phenol red-free Eagle's Minimum Essential Medium
(MEM) supplemented with 10% FBS, 0.1 mmol/L nonessential
amino acids, 1 mmol/L sodium pyruvate, and penicillin–
streptomycin.
Transgenic mice
Ventral prostate lobes were isolated from 12- to 13-week-old
MPAKT (FVB-Tg[Pbsn-AKT1]9Wrs/Nci; ref. 7) and Lo-Myc
(FVB-Tg[Pbsn-MYC]6Key/Nci; ref. 8) transgenicmice and from
age-matched wild-type mice (FVB/N) within 10 minutes after
CO2 euthanasia. Animals' care was in accordance with insti-
tutional guidelines (Institutional Animal Care and Use Com-
mittee). MPAKT mice were generated and raised at the Dana-
Farber Cancer Institute's Facility (7). Lo-MYC and wild-type
mice were obtained from the NCI Frederick mouse repository
and raised at the Johns Hopkins University's Facility (13).
Human prostate tissues
Fresh-frozen, radical prostatectomy samples approved by
the Institutional Review Board were obtained from the insti-
tutional tissue repository at the Dana-Farber Cancer Institute
and Brigham and Women's Hospital (Boston, MA; 61 tumors
and 25 normals).
The percentage of tumor was assessed by top and bottom
frozen sections. To obtain 80% tumor purity, normal tissue
was trimmed and the tumor sample was reembedded in
optimal cutting temperature without thawing. Sections (two
or three 8-mm sections) were cut from these tissue blocks and
DNA, RNA, and proteins were puriﬁed (AllPrep DNA/RNA
Micro Kit; Qiagen Inc.). The remainder was processed for
metabolite extraction (Supplementary Fig. S1C).
Metabolite proﬁling
RWPE–EV, RWPE–AKT1, and RWPE–MYC cells in mono-
layer culture were trypsinized for 4 minutes at 37C. Following
trypsin neutralization with 10% FBS-supplementedMEM, cells
were centrifuged, and cell pellets were washed twice with cold
PBS before freezing. A recovery standard was added before the
ﬁrst step in the extraction process for quality control purposes.
Aqueous methanol extraction was used to remove the protein
fraction. The resulting extract was divided into fractions for
analysis by UPLC/MS-MS (positive mode), UPLC/MS-MS (neg-
ative mode), and GC/MS. Samples were placed on a TurboVap
(Zymark) to remove the organic solvent. Each sample was
frozen and dried under vacuum (see also Supplementary
Materials and Methods).
Absolute quantitation of metabolites
Fifty-six human prostate tissue samples (40 tumors and 16
normals) were used to validate the untargeted metabolite
proﬁling. Oleic, arachidonic, and docosahexaenoic acids, cre-
atine and 2-aminoadipic acid were measured using speciﬁc
internal standards (see also Supplementary Materials and
Methods). Absolute values were expressed as mg/g tissue.
Results were analyzed using the Mann–Whitney test, and
signiﬁcance was deﬁned with P < 0.05.
mRNA expression analysis
Total RNA was isolated from RWPE–EV, RWPE–AKT1, and
RWPE–MYC cells (RNeasy Micro Kit; Qiagen Inc.), prostate
tumors, and normal controls (AllPrep DNA/RNA Micro Kit;
Qiagen Inc.). Real-time PCR was performed using custom
micro ﬂuidic cards (TaqMan Custom Arrays; Applied Biosys-
tems). The list of the probes and primers is provided in
Supplementary Text S1. One-sample t test was applied using
GraphPad Prism 5.0, and signiﬁcance was deﬁned with P < 0.05
(see also Supplementary Materials and Methods).
Immunohistochemistry
Immunohistochemistry for MYC, stathmin, GLUT-1, and
phosphoAKT1 was performed on formalin-ﬁxed parafﬁn-
embedded tissue samples. Immunostaining of human tumors
was scored microscopically counting the percentage of posi-
tive cells (higher or lower than 50%). The entire section was
evaluated and ﬁve representative areas at 20 magniﬁcation
were counted for an average of 500 cells per section. The Fisher
test was applied using GraphPad Prism 5.0, and signiﬁcance
was deﬁned with P < 0.05 (see also Supplementary Materials
and Methods).
Results and Discussion
To focus on an oncogene-speciﬁc context while proﬁling the
metabolic heterogeneity of prostate cancer, we integrated
phosphorylated AKT1- or MYC-associated metabolomic sig-
natures from prostate epithelial cells in monolayer culture,
transgenic mouse prostate, and primary nonmetastatic pros-
tate tumors (Fig. 1). We aimed at identifying patterns of
metabolomic changes that were different for the two onco-
genes but common for the datasets. Human tumors were
assayed for phosphorylated AKT1 and MYC expression by
immunoblotting. All of these tumors were pathologic stage
T2, 22 high Gleason (4þ3 or 4þ4) and 38 low Gleason (3þ3 or
3þ4). Levels of phosphoAKT1 and MYC were not associated
with the Gleason grade of the tumors (Supplementary Fig.
S1A). K-means clustering of phosphorylated AKT1 and MYC
densitometric values (Fig. 1C) was conducted to segregate four
prostate tumor subgroups, that is, phosphoAKT1-high/MYC-
high (6/60, 10%), phosphoAKT1-high/MYC-low (21/60, 35%),
phosphoAKT1-low/MYC-high (9/60, 15%), and phosphoAKT1-
low/MYC-low (24/60, 40%; Fig. 1C and Supplementary Fig.
S1B).
To deﬁne differential metabolic reprogramming induced by
the sole activation of AKT1 or overexpression of MYC, we
performed mass spectrometry–based metabolomics of pros-
tate epithelial nontransformed RWPE-1 cells genetically engi-
neered with constructs encoding myristoylated AKT1 or MYC,
and transgenic mice expressing humanmyristoylated AKT1 or
MYC in the prostate (Fig. 1A and B). More than 50 metabolite
sets (KEGG annotation—Supplementary Dataset S1) were
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tested using single-sample Gene Set Enrichment Analysis
(GSEA). A clear clustering of phosphoAKT1-high versus
MYC-high samples was noticeable within the genetically engi-
neered cell andmouse datasets, with phosphoAKT1-high being
associated with the strongest phenotype in a distinct cluster
compared with MYC-high and control samples that appeared
closer together, yet recognizable as two subclusters (Fig. 2A
and B). Human tumors fell in three clusters (deﬁned by
Silhouette analysis), in which the phosphoAKT1-low/MYC-
high tumors and the phosphoAKT1-high/MYC-low tumors
differentially segregated (Fisher test, P < 0.01; Fig. 2C). Inter-
estingly, although both RWPE–AKT1 and RWPE–MYC cells
showed signiﬁcant changes in intermediates of glucosemetab-
olism and higher enrichment of the glycolysis set compared
with RWPE–EV cells (Fig. 2A), only RWPE–AKT1 cells exhib-
ited accumulation of lactate (aerobic glycolytic phenotype;
Supplementary Fig. S2A). These results were even more pro-
nounced in vivo, with exclusively the MPAKT mouse prostate
samples being characterized by both high levels of lactate and
enrichment of the glycolysis set (Fig. 2B and Supplementary
Fig. S2A). When applied to primary nonmetastatic prostate
tumors stratiﬁed by the expression levels of phospho-AKT1
andMYC, the pathway enrichment analysis revealed thatMYC-
high tumors have a negative enrichment of glycolysis com-
pared with nontumoral prostate tissues (Fig. 2C and Supple-
mentary Fig. S2A). Interestingly, normal prostate tissues may
also be metabolically heterogeneous and exhibit a glycolytic
phenotype (14), potentially attenuating the metabolic differ-
ences between normal and tumor tissue in phosphoAKT1-high
tumors.
Next, we compared directly the AKT1 and MYC metabolic
signatures (Supplementary Datasets S2 and S3). Pathway
enrichment analysis by GSEA was used to determine which
metabolic pathways were commonly enriched across the
genetically engineered models and the prostate tumor sub-
groups deﬁned above, speciﬁcally comparing AKT1-high with
MYC-high background. Gene set-size-normalized enrichment
scores (NES) fromGSEAwere used to determine the extent and
direction of enrichment for each pathway in the three datasets.
Five pathways with highly positive NES and two pathways with
highly negative NES across and common to the datasets were
deﬁned as outliers (Fig. 3A and Supplementary Fig. S3A and
S3B). These results link AKT1 activation with glycolysis and
other glucose-related pathways, including the pentose phos-
phate shunt and fructose metabolism, and MYC overexpres-
sion with deregulated lipid metabolism (Fig. 3A and Supple-
mentary Fig. S3C). On the one hand, enrichment of the glycer-
ophospholipid, glycerolipid, and pantothenate/CoA biosynthe-
sis metabolite sets, as well as higher levels of lipogenesis-
feeding metabolites such as citrate, were distinctively associ-
ated with MYC overexpression in RWPE cells, suggesting a
MYC-dependent deregulation of synthesis and/or turnover of
membrane lipids. Interestingly, higher levels of both omega-3
(docosapentaenoate and docosahexaenoate) and omega-6
(arachidonate, docosadienoate, and dihomo-linolenate) fatty
acids were found in Lo-MYC mice and in phosphoAKT1-low/
MYC-high prostate tumors relative to MPAKT mice and phos-
phoAKT1-high/MYC-low tumors (Supplementary Dataset S2).
Prostate cells may use unsaturated, exogenous essential fatty
acids early during transformation, perhaps as energy sources
via oxidation (15).
As a validation of untargeted metabolomics, absolute con-
centrations of selected metabolites were measured. Oleic,
arachidonic, and docosahexaenoic acids were validated in
phosphoAKT1-high/MYC-low tumors (n ¼ 14) and phos-
phoAKT1-low/MYC-high tumors (n ¼ 5). Oleic acid can be
Figure 1. Integrative models of AKT or MYC-driven prostate
tumorigenesis.Metabolomic proﬁlingwas performed on nontransformed
prostate RWPE-1 cells (A) and mice (B) genetically engineered to
overexpress myristoylated AKT1 or MYC, primary nonmetastatic
prostate tumors (C), and controls. AKT1 and MYC overexpression is
represented by orange and green, respectively. Blue, controls. A,
phosphoAKT1andMYC levels inRWPE–AKT1,RWPE–MYC, andcontrol
(RWPE–EV) cells are shown by immunoblots. B, both MPAKT and
Lo-MYC transgenic mice exhibited prostate intraepithelial neoplasia at
11 to 13 weeks of age, as shown by hematoxylin and eosin (H&E)
staining. Overexpression of phosphoAKT1 and MYC was conﬁrmed by
immunohistochemistry. C, K-means clustering was used to segregate
four prostate tumor subgroups, that is, phosphoAKT1-high/MYC-high
(dark gray dots), phosphoAKT1-high/MYC-low (orange dots),
phosphoAKT1-low/MYC-high (green dots), and phosphoAKT1-low/
MYC-low (light gray dots).
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generated in the cell via desaturation of stearic acid by stearoyl-
CoA delta-9-desaturase (SCD1). Consistent with the semiquan-
titative data, all of these fatty acids were present at a signif-
icantly higher concentration in MYC-high tumors (Fig. 3B).
Additional validation of the untargeted metabolomics includ-
ed the tumor-associated 2-aminoadipic acid, an intermediate
of lysine metabolism, and creatine, which was increased in
phosphoAKT1-high/MYC-low versus phosphoAKT1-low/
MYC-high tumors (Supplementary Fig. S4).
Next, we askedwhether themetabolome changes associated
with the oncogenic transformation of prostate epithelial cells
are accompanied by transcriptional changes in key metabolic
enzymes. Consistent with the metabolite proﬁling of RWPE-1
cells, glycolytic components such as the glucose transporter
GLUT-1 and the hexokinase 2 were increased upon AKT1
overexpression/activation (Fig. 4A). As expected, downstream
targets of AKT1 such asHIF1a (hypoxia-inducible factor 1) and
VEGF-A were induced in AKT1-overexpressing cells (Supple-
mentary Fig. S5A). RWPE–MYC cells showed increased expres-
sion of two key enzymes of the glycerophospholipid metabo-
lism, choline kinase alpha, and cholinephosphotransferase-1
(Fig. 4A). At the proteins level, hexokinase 2 was increased by
AKT1 activation, and choline kinase alpha was induced by
MYC overexpression (Fig. 4B). Consistent with published data
(10), MYC induced the expression of glutaminase, a glutami-
nolytic enzyme responsible for the conversion of glutamine
into glutamate, at both the mRNA and the protein levels (Fig.
4A and B), resulting in an increased amount of glutamate
relative to RWPE–EV. AKT1 activation strongly increased the
expression of the neutral amino acid transporter ASCT2 (Fig.
4A and B). Interestingly, mRNA and protein expression of fatty
acid synthase (FASN) was higher in RWPE–AKT1 and RWPE–
MYC cells compared with RWPE–EV cells (Supplementary Fig.
S5A and S5C), as well as in prostate tumors compared with
normal prostate tissue samples (Supplementary Fig. S5B and
S5C). Although FASN expression can be induced downstream
of AKT1 via mTORC1-mediated SREBP1 (sterol regulatory
element-binding protein 1) activation, a link between
increased de novo lipogenesis and aerobic glycolysis has been
proposed in various tumor types (16, 17), suggesting a multi-
faceted role of FASN.
Sarcosine, an intermediate of the glycine and cholinemetab-
olism previously identiﬁed as a progression marker in prostate
cancer (18), was increased exclusively in the prostate of
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Figure 2. Metabolic pathway analysis in phosphoAKT1-high or MYC-high samples relative to controls. A–C, heatmap representation of NESs (P < 0.05) for
KEGG pathways in individual samples of the three datasets (RWPE-1 cells, MPAKT and Lo-MYCmice, and human prostate tissues). Light blue/yellow colors
are used to denote high/low enrichment, as in the respective color scales. Hierarchical clustering is used for unsupervised identiﬁcation of the higher-level
enrichment classes. Thephenotypic labels of the samples (control, phosphoAKT1-high, andMYC-high) are indicated asacoloredbandon topof the heatmap,
whereas the dendrogram represents the distances among them.
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Lo-MYC mice (Supplementary Fig. S2B). Associated with the
sarcosine increase were a concomitant elevation of the inter-
mediate betaine and a decrease in glycine levels (Supplemen-
tary Fig. S2B). These results reﬂect a dysregulation of the
sarcosine pathway by MYC.
To determine whether genomic alterations at the PTEN or
MYC loci are predictive of active AKT1 or MYC overexpression
in prostate tumors, we performed SNP arrays using genomic
DNA isolated from the same sections of each tumor or non-
tumoral matched control sample assayed by immunoblotting
(phosphorylated AKT1 and MYC). SNP arrays revealed that
20% of these tumors harbored 10q loss and 18% harbored 8q
gain, including the MYC locus (Supplementary Fig. S6), where-
as cooccurrence of PTEN loss andMYC copy gain was found in
Pathway Cell Mouse Human Mean
Glycolysis gluconeogenesis 1.36 1.28 1.59 1.41
Fructose and mannose metabolism 1.46 1.22 1.31 1.33
Pentose phosphate pathway 1.46 0.99 1.42 1.29
Propanoate metabolism 0.97 1.42 1.18 1.19
Amino sugar and nucleotide sugar metabolism 1.29 0.66 1.53 1.16
Glycerolipid metabolism –1.04 –0.99 –0.85 –0.96
Fatty acid biosynthesis –0.95 –0.87 –1.34 –1.05
Arachidonic acid Docosahexaenoic acid Oleic acid
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Figure 3. Overall differential metabolite set enrichments in phosphoAKT1-high versus MYC-high samples. A, simultaneous GSEA measurements in all
three datasets (cultured cells, mouse prostate, and human tumors) are shown (left). This information is depicted as dots in three-dimensional space,
where each dot represents a particular pathway and each dimension a dataset. Enrichment of a pathway in phosphoAKT1-high versus MYC-high
samples or vice versa is deﬁned by a positive or negative score, respectively. The top ﬁve positively enriched pathways (i.e., in phosphoAKT1-high
samples) and the top two negatively enriched pathways (i.e., in MYC-high samples) in all three datasets, as identiﬁed with outlier analysis
(Supplementary Fig. S3), are shown as orange and green dots, respectively. NESs of the seven pathways identiﬁed as outliers in the three datasets and
the average of these scores are shown per each set (KEGG pathway) on the right. B, semiquantitative (top) and absolute (bottom) measurements of
arachidonic acid, docosahexaenoic acid, and oleic acid in phosphoAKT1-high/MYC-low (orange) and phosphoAKT1-low/MYC-high (green) tumor
samples. The Mann–Whitney test was applied; , P < 0.05 and , P < 0.01.
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3%of tumors, consistentwith published data (19). Importantly,
the genomic alterations accounted for 26% (7/27) of phos-
phoAKT1-high tumors and for 13% (2/15) of MYC-high tumors
(Supplementary Fig. S6), as expected from previous reports
(20).
Finally, to identify unique mRNA expression changes in
phosphoAKT1-high/MYC-low and phosphoAKT1-low/MYC-
high prostate tumors, we performed a qPCR-based expression
proﬁling analysis of 28 metabolic genes (Supplementary Fig.
S5D) in tumor relative to normal prostate tissues. Consistent
with the MYC-dependent negative enrichment for the glyco-
lytic pathway (Fig. 2C and Supplementary Fig. S2A), high MYC
expression in a phosphoAKT1-low context in human tumors
was associated with decreased mRNA expression of GLUT-1
(Fig. 4C). This ﬁndingwas speciﬁc to theMYC-high tumors and
not generalizable to all tumors versus normal prostate tissues
(Supplementary Fig. S5B). Also, no decrease in GLUT-1 expres-
sion was found in phosphoAKT1-high/MYC-high tumors (Fig.
4C). A signiﬁcant association between GLUT-1 high expression
and phosphoAKT1-high status was found by immunohis-
tochemistry in a subset of this cohort (Fig. 4D and Supple-
mentary Fig. S5C). Seven of 14 phosphoAKT1-low tumors were
MYC-high, and only 14% (1/7) of these showed high GLUT-1,
whereas 85% (6/7) had low or no GLUT-1 expression (Fig. 4D).
Altogether, these results suggest that AKT1 activation may be
critical tomaintain high GLUT-1 levels in prostate cancer cells,
and that AKT1-independent MYC activation can potentially
affect glucose uptake in prostate tumors.
In summary, our data demonstrate that individual prostate
tumors have distinct metabolic phenotypes, resulting from
their genetic complexity, and reveal a novel potential meta-
bolic role for MYC in prostate cancer. The evidence provided
Figure 4. AKT1- and MYC-dependent regulation of metabolic gene expression. A, relative qPCR analysis of mRNA levels of genes of glucose,
glycerophospholipid, andglutaminemetabolism inRWPE–AKT1 (orangebars) andRWPE–MYC (green bars) cells normalized toRWPE–EV (bluebars) cells. B,
immunoblotting of hexokinase 2 (HK2), the glutamine transporter ASCT2, glutaminase (GLS), and choline kinase alpha (CHKa) in RWPE–AKT1, RWPE–MYC,
and RWPE–EV cells. C, relative qPCR analysis of mRNA levels of the glucose transporter GLUT-1 in phosphoAKT1-high/MYC-low (orange bar; n ¼ 13),
phosphoAKT1-low/MYC-high (green bar; n ¼ 5), and phosphoAKT1-high/MYC-high (dark gray bar; n¼ 3) prostate tumors versus normal prostate samples
(blue bar; n¼9). D, hematoxylin and eosin (H&E) and immunohistochemical staining forMYC, stathmin (anAKTdownstream target used as a surrogate of AKT
activity), and GLUT-1 in representative cases of phosphoAKT1-low/MYC-high and phosphoAKT1-high/MYC-low prostate tumors. Red cells (arrows)
represent a positive control forGLUT-1 staining.One-sample t testwasperformedusing average fold changeof at least three experiments (A) or samples (C); ,
P < 0.05; , P < 0.01; and , P < 0.001.
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links AKT1 or MYC activation with differential deregulation of
glucose-related pathways aswell as lipidmetabolism in human
prostate cancer. To our knowledge, this is the ﬁrst report of
oncogene-associated metabolic signatures as the result of an
integrative analysis of cultured cells, mouse models, and
human tumors. This opens novel avenues for the metabolic
imaging and therapeutic targeting of patients with prostate
cancer.
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